Myelofibrosis is a bone marrow disorder that results in accelerated fibrosis and the replacement of the bone marrow by fibrotic tissue like a scar. The disease may be caused by somatic mutations o the JAK2 gene.
| 1. |
Kralovics R et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders.
|
| 2. |
Cassinat B et al. (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia.
|
| 3. |
Passamonti F et al. (2014) JAK inhibitor in CALR-mutant myelofibrosis.
|
| 4. |
Cazzola M et al. (2014) JAK inhibitor in CALR-mutant myelofibrosis.
|
| 5. |
Jutzi JS et al. (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.
|
| 6. |
Kaufmann KB et al. (2012) A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.
|
| 7. |
Pardanani AD et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
|
| 8. |
Pikman Y et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
|
| 9. |
Bonduel M et al. (1998) Familial idiopathic myelofibrosis and multiple hemangiomas.
|
| 10. |
Sieff CA et al. (1980) Familial myelofibrosis.
|
| 11. |
Delhommeau F et al. (2009) Mutation in TET2 in myeloid cancers.
|
| 12. |
Arranz L et al. (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
|
| 13. |
Méndez-Ferrer S et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche.
|
| 14. |
Méndez-Ferrer S et al. (2008) Haematopoietic stem cell release is regulated by circadian oscillations.
|
| 15. |
Baxter EJ et al. () Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
|
| 16. |
Orphanet article Orphanet ID 824
|
| 17. |
OMIM.ORG article Omim 254450
|
| 18. |
Wikipedia article Wikipedia EN (Myelofibrosis)
|